Latest Commercial Expansion News

Page 9 of 9
LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.
Ada Torres
Ada Torres
29 Apr 2025
Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.
Victor Sage
Victor Sage
18 Feb 2025
Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.
Ada Torres
Ada Torres
17 Feb 2025
Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.
Ada Torres
Ada Torres
14 Feb 2025
Micro-X Limited has requested an immediate voluntary suspension of its shares on the ASX, pending a forthcoming equity raising announcement expected by February 10.
Ada Torres
Ada Torres
4 Feb 2025
Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.
Ada Torres
Ada Torres
31 Jan 2025
Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.
Ada Torres
Ada Torres
31 Jan 2025
SportsHero Limited has inked a five-year partnership with Indonesia's Indosat Ooredoo Hutchison to market its Family Game Room product, alongside securing a $1 million debt facility to support its expansion plans.
Sophie Babbage
Sophie Babbage
30 Jan 2025
OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.
Victor Sage
Victor Sage
30 Jan 2025
Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.
Ada Torres
Ada Torres
23 Jan 2025
Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.
Ada Torres
Ada Torres
23 Jan 2025